Last Updated:
Enteromix, a personalized mRNA cancer vaccine, showed 100% efficacy and safety in trials. Developed by Russian institutes, it awaits Ministry of Health approval for public use.
With trials completed successfully, the only remaining step is regulatory clearance. (AI-generated pic)
In what could be a groundbreaking achievement in the fight against cancer, a revolutionary mRNA-based vaccine called Enteromix has demonstrated 100% efficacy and safety in clinical trials.
The treatment, which targets and destroys cancer cells while significantly shrinking large tumours, is now awaiting final approval from the Ministry of Health before it can be made available to the public, RT India reported.
Developed using cutting-edge mRNA technology — similar to that used in Covid-19 vaccines — Enteromix works by training the immune system to recognize and eliminate cancer cells. Unlike traditional treatments such as chemotherapy or radiation, the vaccine is personalized for each patient, making it a tailored approach to cancer therapy.
No serious side effects were reported, and patients tolerated the treatment well.
Earlier, it was announced that Russia had started clinical trials of the new EnteroMix oncolytic vaccine with 48 volunteers participating. The drug was developed by the Russian Ministry of Health’s National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences (RAS).
According to a report in MedPath, the vaccine uses four harmless viruses to attack and destroy cancerous tumors while also boosting the patient’s immune system to fight the cancer. Enteromix went through several years of early testing and has been shown to slow down tumor growth — and in some cases, completely destroy the cancer.
The start of the clinical trial was announced at the St. Petersburg International Economic Forum (SPIEF 2025), held from June 18 to 21 in northern Russia. The event, organized by the Roscongress agency under the Russian President’s office, showcased Russia’s progress in medical research and biotechnology.
With trials completed successfully, the only remaining step is regulatory clearance. The Ministry of Health is expected to conduct a final review of the data in the coming weeks.
If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public, potentially transforming the landscape of oncology and offering new hope to millions.
Manisha Roy is a Senior Sub-Editor at News18.com’s general desk. She comes with an experience of over 5 years in media industry. She covers politics and other hard news. She can be contacted at Manisha.Roy@nw18…Read More
Manisha Roy is a Senior Sub-Editor at News18.com’s general desk. She comes with an experience of over 5 years in media industry. She covers politics and other hard news. She can be contacted at Manisha.Roy@nw18… Read More
September 06, 2025, 23:11 IST
Read More
